Skip to main content
main-content

Latest news stories

Latest news stories

09-06-2019 | Renal cell carcinoma | ASCO 2019 | News

KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

07-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Prolonged survival possible with pembrolizumab in advanced NSCLC

Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.

07-06-2019 | Small-cell lung cancer | ASCO 2019 | News

Lurbinectedin shows potential for second-line SCLC treatment

Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.

05-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

EGFR–cMET bispecific antibody shows efficacy in NSCLC patients with high unmet needs

Preliminary findings for a first-in-human study of JNJ-372 – a bispecific IgG antibody targeting both the EGFR and cMET receptors – have been reported at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

05-06-2019 | Urothelial cancer | ASCO 2019 | News

Positive phase II findings for enfortumab vedotin in advanced urothelial cancer

Preliminary results from a pivotal trial of enfortumab vedotin, an antibody–drug conjugate targeting Nectin-4, show a “clinically meaningful” response in patients with unresectable locally advanced or metastatic urothelial cancer.

04-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Metformin addition ruled out for nondiabetic men with metastatic CRPC

The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.

03-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Olaparib response may depend on DDR mutation type in mCRPC

The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.

03-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

HER3-targeted antibody–drug conjugate shows promise for TKI-resistant NSCLC

Early results suggest that a novel antibody–drug conjugate directed against HER3 has antitumor activity and manageable safety in patients with EGFR-mutated metastatic non-small-cell lung cancer and acquired resistance to EGFR–tyrosine kinase inhibitors.

02-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | News

TITAN: OS benefit seen with apalutamide in metastatic CSPC setting

Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.

01-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

30-05-2019 | Urothelial cancer | News

AE link to response shown in PD-1/PD-L1 inhibitor-treated urothelial cancer

Individuals with urothelial cancer who respond to treatment with PD-1 or PD-L1 inhibitors are more likely to report adverse events of special interest, including immune-mediated events, than nonresponders, results of a pooled analysis show.

29-05-2019 | Non-small cell lung cancer | News

First-line atezolizumab–chemotherapy an option for nonmutated metastatic NSCLC

Patients with treatment-naïve, nonmutated, nonsquamous, advanced non-small-cell lung cancer derive a significant survival benefit from the addition of the PD-L1 inhibitor atezolizumab to chemotherapy, indicate phase III trial findings.

28-05-2019 | Prostate cancer | Highlight | News

Socioeconomic factors major players in prostate cancer racial disparity

Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.

24-05-2019 | Small-cell lung cancer | News

Twice-daily radiotherapy may increase brain metastasis risk in SCLC

Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.

23-05-2019 | Urothelial cancer | News

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

22-05-2019 | Clinical trial | News

Waterfall plot diagrams may overestimate response rate

Waterfall plots visually overestimate the tumor response rate to agents being tested in clinical trials, US researchers warn in JAMA Network Open.

21-05-2019 | Mesothelioma | News

No benefit with nintedanib in advanced malignant pleural mesothelioma

Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.

20-05-2019 | Prostate cancer | News

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

17-05-2019 | Small-cell lung cancer | Highlight | News

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

17-05-2019 | FDA | News

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

Image Credits